Exploring the biology of cancer of unknown primary: Breakthroughs and drawbacks

European Journal of Clinical Investigation

Volumn 43, Issue 5, 2013, Pages 491-500

  Kamposioras, Konstantinos ^a   Pentheroudakis, George ^b   Pavlidis, Nicholas ^b  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Biology; Cancer of unknown primary; Metastases; Tumour regression

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; GELATINASE B; GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR; MICRORNA; NERVE CELL ADHESION MOLECULE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P21; PROTEIN P53; SCATTER FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; VIMENTIN;

ANEUPLOIDY; ANGIOGENESIS; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CELL DEATH; CELL GROWTH; CELL INVASION; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CIRCULATING TUMOR CELL; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GROWTH; HUMAN; HYPOXIA; KARYOTYPE; METASTASIS; MOLECULAR BIOLOGY; MONONUCLEAR CELL; ONCOGENE; ONCOGENE C KIT; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; NEOPLASMS, UNKNOWN PRIMARY; PHENOTYPE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84876480383     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12062     Document Type: Review

References (53)

1. Pavlidis N, Fizazi K. Carcinoma of Unknown Primary. Crit Rev Oncol Hematol 2009;69:271-8.
2. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet 2012;9824:1428-35.
3. Rajagopalan H, Lengauer C. Aneuploidy and cancer. Nature 2004;432:338-41.
4. Hedley DW, Leary JA, Kirsten F. Metastatic adenocarcinoma of unknown primary site: abnormalities of cellular DNA content and survival. Eur J Cancer Clin Oncol 1985;21:185-9.
5. Abbruzzese JL, Lenzi R, Raber MN, Pathak S, Frost P. The biology of unknown primary tumors. Semin Oncol 1993;20:238-43.
6. Motzer RJ, Rodriguez E, Reuter VE, Bosl GJ, Mazumdar M, Chaganti RS. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol 1995;13:274-82.
7. Summersgill B, Goker H, Osin P, Huddart R, Horwich A, Fisher C et al. Establishing germ cell origin of undifferentiated tumors by identifying gain of 12p material using comparative genomic hybridization analysis of paraffin-embedded samples. Diagn Mol Pathol 1998;7:260-6.
8. Ilson DH, Motzer RJ, Rodriguez E, Chaganti RS, Bosl GJ. Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site. Semin Oncol 1993;20:229-37.
9. Pantou D, Tsarouha H, Papadopoulou A, Mahaira L, Kyriazoglou I, Apostolikas N et al. Cytogenetic profile of unknown primary tumors: clues for their pathogenesis and clinical management. Neoplasia 2003;5:23-31.
10. Speel EJ, van de Wouw AJ, Claessen SM, Haesevoets A, Hopman AH, van der Wurff AA et al. Molecular evidence for a clonal relationship between multiple lesions in patients with unknown primary adenocarcinoma. Int J Cancer 2008;123:1292-300.
11. Pavlidis N, Briassoulis E, Bai M, Fountzilas G, Agnantis N. Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res 1995;1:2563-67.
12. Hainsworth JD, Lennington WJ, Greco FA. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 2000;1:632-5.
13. van de Wouw AJ, Jansen RLH, Griffioen AW, Hillen HFP. Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res 2004;24:297-302.
14. Rashid A, Hess KR, Lenzi R, Raber MN, Abbruzzese JL, Varadhachary GR. Overexpression and prevalence of molecular markers in patients with cancer of unknown primary (CUP). Proc Am Soc Clin Oncol 2005;2:9683.
15. Dova L, Pentheroudakis G, Georgiou I, Malamou-Mitsi V, Vartholomatos G, Fountzilas G et al. Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target? Clin Exp Metastasis 2007;24:79-86.
16. Massard C, Voigt JJ, Laplanche A, Culine S, Lortholary A, Bugat R et al. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer 2007;97:857-61.
17. Koo JS, Kim H. Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary. Tumour Biol 2011;32:893-904.
18. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002;3:655-64.
19. O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 2006;16:92-9.
20. Dova L, Pentheroudakis G, Golfinopoulos V, Malamou-Mitsi V, Georgiou I, Vartholomatos G et al. Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit. J Cancer Res Clin Oncol 2008;134:697-704.
21. Briasoulis E, Tsokos M, Fountzilas G, Bafaloukos D, Kosmidis P, Samantas E et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. Anticancer Res 1998;18:1907-14.
22. Soussi T, Ishioka C, Claustres M, Béroud C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer 2006;6:83-90.
23. Bar-Eli M, Abbruzzese JL, Lee-Jackson D et al. p53 gene mutation spectrum in human unknown primary tumors. Anticancer Res 1993;13:1619-23.
24. Gottschlich S, Schuhmacher O, Gorogh T, Hoffmann M, Maune S. Analysis of the p53 gene status of lymph node metastasis in the head and neck region in occult primary cancer. Laryngorhinootologie 2000;79:434-7.
25. Vousden KH, Woude GF. The ins and outs of p53. Nat Cell Biol 2000;2:E178-80.
26. Makri A, Pissimissis N, Lembessis P, Polychronakos C, Koutsilieris M. The kisspeptin (KiSS-1)/GPR54 system in cancer biology. Cancer Treat Rev 2008;34:682-92.
27. Dova L, Golfinopoulos V, Pentheroudakis G, Georgiou I, Pavlidis N. Systemic dissemination in cancer of unknown primary is independent of mutational inactivation of the KiSS-1 metastasis-suppressor gene. Pathol Oncol Res 2008;14:239-41.
28. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008;14:1291-5.
29. Souglakos J, Pentheroudakis G, Papadaki C, Cervantes A, Petrakis D, Roodriguez-Braun E et al. Prognostic significance of gene expression profile in patients with carcinomas of unknown primary. Ann Oncol 2010;128P:viii55.
30. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H et al. Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer 2005;5:25-32.
31. Agarwal B, Das P, Naresh KN, Borges AM. Angiogenic ability of metastatic squamous carcinoma in the cervical lymph nodes from unknown primary tumours. J Clin Pathol 2011;64:765-70.
32. Hainsworth JD, Spigel DR, Thompson DS, Murphy PB, Lane CM, Waterhouse DM et al. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist 2009;14:1189-97.
33. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie pearl cancer research network. J Clin Oncol 2007;25:1747-52.
34. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010;16:5928-35.
35. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010;101:293-9.
36. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H et al. Matrix metalloproteinases in carcinoma of unknown primary. Cancer 2005;104:2282-7.
37. Stoyianni A, Goussia A, Pentheroudakis G, Siozopoulou V, Ioachim E, Krikelis D et al. Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility. Anticancer Res 2012;32:1273-81.
38. Sampieri K, Fodde R. Cancer stem cells and metastasis. Semin Cancer Biol 2012;22(3):187-93.
39. Krikelis D, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Petrakis D et al. Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary. Clin Exp Metastasis 2012;29:603-14.
40. Stella GM, Benvenuti S, Gramaglia D, Scarpa A, Tomezzoli A, Cassoni P et al. MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat 2011;32:44-50.
41. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 2012;9:314-26.
42. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
43. Golfinopoulos V, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Krikelis D et al. Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases. Ann Oncol 2012;23:2725-30.
44. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:121-30.
45. Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2012. [Epub ahead of print].
46. Pentheroudakis G, Apostolaki S, Stoyianni A, Karaxalios D, Patramani S, Goussia A et al. Circulating tumour cells in cancer of unknown primary site:correlation with clinico pathologic characteristics and prognosis. Ann Oncol 2010; 21:Abstr 865: viii269.
47. Pentheroudakis G, Briasoulis E, Pavlidis N. Cancer of unknown primary site: missing primary or missing biology? Oncologist 2007;12:418-25.
48. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007;43:2026-36.
49. Monzon FA, Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med 2010;134:216-24.
50. Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the sarah cannon research institute. J Clin Oncol 2013;31(2):217-23.
51. Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. Cancer Treat Rev 2009;35:221-7.
52. Pentheroudakis G, Spector Y, Krikelis D, Kotoula V, Meiri E, Malamou-Mitsi V et al. Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors. Clin Exp Metastasis 2012. [Epub ahead of print].
53. Hillen HF, Hak LE, Joosten-Achjanie SR, Arends JW. Microvessel density in unknown primary tumors. Int J Cancer 1997;74:81-5.